Christine Bestvina, MD - UChicago Medicine

Dr. Christine M. Bestvina

Claim this profile

University of Chicago Comprehensive Cancer Center

Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
21 reported clinical trials
38 drugs studied

Area of expertise

1

Lung Cancer

Global Leader

Christine M. Bestvina has run 19 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Non-Small Cell Lung Cancer

Global Leader

Christine M. Bestvina has run 11 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.

University Of Chicago Comprehensive Cancer Center

Image of trial facility.

UC Comprehensive Cancer Center At Silver Cross

Clinical Trials Christine M. Bestvina is currently running

Image of trial facility.

Durvalumab + Radiation

for Small Cell Lung Cancer

This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.

Recruiting

1 award

Phase 2

14 criteria

Image of trial facility.

LY4050784

for Advanced Cancer

The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.

Recruiting

1 award

Phase 1

2 criteria

More about Christine M. Bestvina

Clinical Trial Related

6 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 6 Active Clinical Trials

Treatments Christine M. Bestvina has experience with

  • Carboplatin
  • Pemetrexed
  • Pembrolizumab
  • Nivolumab
  • Paclitaxel
  • Durvalumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Christine M. Bestvina specialize in?

Is Christine M. Bestvina currently recruiting for clinical trials?

Are there any treatments that Christine M. Bestvina has studied deeply?

What is the best way to schedule an appointment with Christine M. Bestvina?

What is the office address of Christine M. Bestvina?

Is there any support for travel costs?